The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System

Purpose

A Prospective, Multicenter, Randomized, Pivotal Study of the May Health System in Transvaginal Ablation of Ovarian Tissue under Ultrasound Guidance in Women with Infertility due to Polycystic Ovary Syndrome

Conditions

  • Polycystic Ovary Syndrome
  • Infertility, Female

Eligibility

Eligible Ages
Between 18 Years and 40 Years
Eligible Genders
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Age ≥ 18 to ≤ 40 years 2. Infertility associated with oligo- or anovulation, AND EITHER: 2.1 Ultrasonographic evidence of PCOS (ovarian volume ≥ 10 mL and/or ovarian antral follicle count per ovary ≥ 20) OR 2.2 Evidence of hyperandrogenemia: either clinical (hirsutism defined as modified Ferriman-Gallwey (mFG) level ≥ 4-6 depending on ethnicity) or biochemical (raised serum concentration of androgens, testosterone ≥ 2.5 nmol/L, or FAI > 4) 3. At least one ovary with ovarian volume ≥ 10.0 mL and neither ovary > 23.0 mL 4. Ovarian accessibility: determined by ability to bring transvaginal ultrasound transducer into close proximity to at least one ovary. (Note: In the situation where only one ovary is appropriately sized according to the preceding criterion, then this requirement applies to the qualifying ovary.) 5. At least one patent fallopian tube and normal uterine cavity as determined by sonohysterogram, hysterosalpingogram, or hysteroscopy/laparoscopy within the last 3 years 6. Has not responded to first-line ovulation induction treatment or is contraindicated for, or declines, such treatment 7. Currently seeking immediate fertility 8. Willing to comply with Clinical Investigation Plan-specified follow-up evaluations 9. Ability to understand study requirements and has sufficient fluency in one of the approved written translations of the Patient Information and Informed consent form 10. Signed informed consent

Exclusion Criteria

  1. Currently pregnant 2. BMI > 40 3. Marked hyperandrogenism (FAI > 15) 4. Poor glycemic level control defined as glycohemoglobin (HbA1c) level > 6.5% 5. Bleeding disorders, such as von Willebrand disease, thrombocytopenia, current use of anticoagulation medication, etc. 6. Active genital or urinary tract infection at the time of the procedure 7. Patient with known or suspected periovarian adhesions 8. Previous ovarian or tubal surgery such as ovarian drilling, endometriosis surgery, ovarian cysts surgery or sterilization procedure (i.e., tubal ligation) 9. Transvaginal ultrasound transducer cannot be brought into proximity of at least one ovary 10. Presence of a pathologic cyst (i.e. endometrioma, dermoid, etc.) of any size, or functional cyst >15 mm on transvaginal ultrasound 11. Received > 2 cycles of treatment with gonadotropins without a resulting pregnancy 12. Contraindicated to or known previous reaction to anesthesia or sedation regimen 13. Patient not willing to stop all concomitant first-line ovulation induction treatment (clomiphene citrate, letrozole, as well as metformin unless metformin is required for glycemic control) until the 3-month endpoint is reached 14. Male partner's total motile sperm count (TMSC) < 10 million (unless participant is planning donor sperm IUI) 15. Patient is currently participating in another investigational drug or device study that clinically interferes with the endpoints of this study

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Intervention Model Description
Control arm has the option to crossover to receive the May Health procedure after completion of the 3 month primary endpoint visit.
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Device arm 		May Health procedure performed with the use of the May Health system intended for transvaginal ablation of ovarian tissue under ultrasound visualization in women with infertility due to Polycystic Ovary Syndrome.
  • Device: May Health System
    The intervention includes the short-term use of the May Health System, which is comprised of three elements: (1) the May Health Needle-Catheter Ablation Device (NCAD) (the Device) a 16 gauge echogenic needle including a bipolar temperature-controlled RF ablation catheter which is clipped and secured onto a vaginal ultrasound probe; (2) the May Health Adapter which is clipped onto the ultrasound probe; and (3) the May Health Generator: a bipolar radiofrequency (RF) ablation platform utilizing the single use May Health NCAD for ovarian tissue ablation. Once the patient is under conscious sedation, the physician guides the May Health system transvaginally with the use of a transvaginal ultrasound. Once the May Health device is safely and securely positioned, the physician will deliver radio frequency energy inside the ovary in order to ablate the tissue.
No Intervention
Control arm 		No fertility medication. Crossover participants who choose to crossover after the 3 month follow up visit will restart follow up as per the Device arm.

Recruiting Locations

UT Health San Antonio
San Antonio, Texas 78229
Contact:
Marisa Fernandez, BSN, RN
210-450-8016
fernandezm10@uthscsa.edu

More Details

Status
Recruiting
Sponsor
May Health

Study Contact

Bertha Torres
7144571229
Bertha@Mayhealth.com

Detailed Description

The objective of the study is to provide evidence for the safety and effectiveness of the May Health System in transvaginal ablation of ovarian tissue under transvaginal ultrasound guidance to restore ovulation in women with infertility due to polycystic ovary syndrome (PCOS) who have not responded to first-line ovulation induction treatment or are contraindicated for or decline such treatment.